Despite an uptick in profits, Dr Reddy’s Laboratories experienced a decline in share value. Analysts continue to express optimism, keeping a bullish outlook on the stock. While there are immediate hurdles to navigate, promising catalysts for growth lie ahead, notably with the anticipated launches of Semaglutide and Abatacept.
Originally published by The Economic Times https://economictimes.indiatimes.com/markets